

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:26:27 +0000
To: Folkers, Greg (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Cc: NIAID OD AM
Subject: RE: ASF RE: Dr. Fauci video request: Public Service Recognition Week
Attachments: ASF public service recognition - with tracked edits -05-05-2020.docx



See minor tracked changes.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 6:16 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Awwad, David (NIH/NIAID) [C] (b) (6) >
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: ASF RE: Dr. Fauci video request: Public Service Recognition Week

ASF –

Here is a short script for Public Service Recognition Week. We agreed to do a short video
ASF – can u tweak as needed?
David, could u record in some format that is easy? Cell phone or other I just learned they want by COB tomorrow

<< File: ASF public service recognition.docx >>

From: Seigfreid, Kim (NIH/OD) [E] (b) (6)>
Sent: Monday, April 27, 2020 4:30 PM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] (b) (6)>; Polimeni, Lydia (NIH/OD) [E] (b) (6)
Subject: Dr. Fauci video request: Public Service Recognition Week

Hi there,

Please see below. HHS is taking over the Partnership for Public Service IG account next week for Public Service Recognition Week. They asked if Dr. Fauci would be willing to do a short 30-second or less pre-recorded video thanking public servants for their work. It would be featured during the takeover, and also on NIH's other sm handles next week. It can be taken on a cell phone as sm does not require higher resolution. Let me know if you would like to accept or decline the request.

Many thanks,
Kim

Kim Seigfreid
Social Media Lead
NIH Office of Communications and Public Liaison
ph: (b) (6)
(b) (6)

From: Muhammad, Janell (HHS/ASPA) <(b) (6)>
Sent: Monday, April 27, 2020 4:10 PM
To: Seigfreid, Kim (NIH/OD) [E] (b) (6)>; Channer, Amber (OS/OASH) (b) (6)>; Foster, Timothy (OS/ASPA) (b) (6)>
Cc: Palczewski, Andrew (HHS/ASPA) <(b) (6)>; Pratt, Michael (OS/ASPA) <(b) (6)>; Sherman, Jennifer (HHS/OASH) (b) (6)
Wilker, Michael (HHS/ASPA) (b) (6); Dine, Brooke (HHS/ASPA) (b) (6)
Subject: Public Service Recognition Week

Hello All,

Hope everyone is holding up well!

OHR is taking over the Partnership for Public Service (PPS) Instagram account during Public Service Recognition Week (May 3-9, 2020). The OHR team has reached out about wanting to develop a senior leader "mashup" video —perhaps including the DepSec. T

They asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci and the SG doing a pre-recorded video thanking public servants for their work.

I wanted to gather the troops so we can identify what all is being planned for this week of recognition and provide a POC for OHR if the request is feasible.

Happy to set up a call, if that is needed to discuss further.

Thanks,
Janell

Janell Muhammad

ASPA Digital Engagement (Team Lead)
U.S. Department of Health and Human Services

Email: (b) (6)

Office: (b) (6)

iPhone: (b) (6)

[HHS on Facebook](#) | [HHS on Twitter](#) | [HHS Latino](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:05:41 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft PR re: launch of ACTT 2 COVID treatment study

See my minor change of my comment in red.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, May 5, 2020 1:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FOR ASF REVIEW: Draft PR re: launch of ACTT 2 COVID treatment study

Hi Dr. Fauci,

Please find attached for your review a draft press release to announce the launch of the ACTT 2 COVID-19 treatment trial (remdesivir and baricitinib). Below is your draft quote:

“We now have solid data showing that remdesivir diminishes to a modest degree the time to recovery for people hospitalized with COVID-19,” said NIAID Director Anthony S. Fauci, M.D. “ACTT 2 will examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients, including improving mortality outcomes.”

The trial may start enrollment tomorrow.

Thanks much,
Kathy

Kathy Stover
Branch Chief
News and Science Writing Branch
National Institute of Allergy and Infectious Diseases (NIAID)
Office of Communications and Government Relations
National Institutes of Health/HHS
31 Center Drive, Room 7A17E
Bethesda, MD 20892
Phone: (b) (6)
E-mail: (b) (6)
NIAID Media Line: (301) 402-1663

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 22:00:53 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: COVID-19, (b) (4)
Attachments: Birman_Fauci_Azar_Adams_Hahn_letter_May_05_2020.docx

Please take a look at this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: (b) (4)
Sent: Tuesday, May 5, 2020 2:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Azar, Alex M. (b) (6); Adams, Jerome M <(b) (6)>; Hahn, Stephen (FDA) (b) (6)
Subject: RE: COVID-19, (b) (4)

Dr. Anthony S. Fauci, M.D.
Director, NIAID
Mr. Alex M. Azar II
Secretary, HHS
Dr. Jerome M. Adams, M.D.
Surgeon General, HHS
Dr. Stephen M. Hahn, M.D.
Commissioner of FDA, HHS

Dear Dr. Fauci,
Dear Mr. Azar,
Dear Dr. Adams,
Dear Dr. Hahn,

(b) (4)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 21:17:33 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Dieffenbach, Carl (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Graham, Barney (NIH/VRC) [E];Marovich, Mary (NIH/NIAID) [E]
Subject: RE: D614G mutation paper

Thanks, John. [REDACTED] (b) (5)

[REDACTED] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6)>
Sent: Tuesday, May 5, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6); Erbelding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6); Dieffenbach, Carl (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [REDACTED] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6); Graham, Barney (NIH/VRC) [E] [REDACTED] (b) (6)>; Marovich, Mary (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: D614G mutation paper

Tony,

David Montefiori will be on CNN tonight related to this paper – and story in in major newspapers. I spoke with David to get some advance info. The paper is out in BioRxiv.
Few key points

John

Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2

Korber B¹, Fischer WM¹, Gnanakaran S¹, Yoon H¹, Theiler J¹, Abfalterer W¹, Foley B¹, Giorgi EE¹, Bhattacharya T¹, Parker MD³, Partridge DG⁴, Evans CM⁴, de Silva TI^{4,5}, on behalf of the Sheffield COVID-19 Genomics Group[#], LaBranche CC², and Montefiori DC²

Summary

We have developed an analysis pipeline to facilitate real-time mutation tracking in SARS-CoV-2, focusing initially on the Spike (S) protein because it mediates infection of human cells and is the target of most vaccine strategies and antibody-based therapeutics. To date we have identified fourteen mutations in Spike that are accumulating. Mutations are considered in a broader phylogenetic context, geographically, and over time, to provide an early warning system to reveal mutations that may confer selective advantages in transmission or resistance to interventions. Each one is evaluated for evidence of positive selection, and the implications of the mutation are explored through structural modeling. The mutation Spike D614G is of urgent concern; it began spreading in Europe in early February, and when introduced to new regions it rapidly becomes the dominant form. Also, we present evidence of recombination between locally circulating strains, indicative of multiple strain infections. These findings have important implications for SARS-CoV-2 transmission, pathogenesis and immune interventions.

From: David Montefiori, Ph.D. [REDACTED] (b) (6)

Sent: Tuesday, May 5, 2020 1:23 PM

To: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6)

Subject: RE: D614G

John,

I thought you should know that the D614G story is getting a lot of press attention today. I story came out in the LA Times this morning that probably started it all. It will likely be on CNN tonight, and maybe other networks.

Just a heads-up.

David

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 20:43:39 +0000
To: Billet, Courtney (NIH/NIAID) [E]; NIAID OD AM
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
Attachments: Script to honor Avi Schiffmann - 05-05-2020.docx

Here is my tracked version of the Schiffmann script.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, May 5, 2020 3:06 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

OK – so this is the ask from the Webby awards: a short recorded video message. They have sent a proposed script below -- just an example – obviously we're free to change it. Avi is a pretty extraordinary kid. 17 years old!

Here is the site he created, back in early January. He's aggregating data from WHO, CDC, and other sources: <https://ncov2019.live/>

NBC Today story: <https://www.today.com/parents/17-year-old-built-website-track-coronavirus-t175245>

New Yorker article about him: <https://www.newyorker.com/magazine/2020/03/30/the-high-schooler-who-became-a-covid-19-watchdog>

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Tuesday, May 5, 2020 2:32 PM

To: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Courtney,

This would be a pre-recorded message with Dr Fauci solo. He would set up Avi's award and help to celebrate his Webby moment for him. Avi will be sending us his 5 word Webby speech which will then follow Dr. Fauci's intro. Below is a draft of the introduction for him, let us know if he would like to make any edits/changes. I've also attached the format for taping on his phone/computer. Please let me know if you need any additional information and hoping we can make it work.

Thank you so much

Best

Lesley

DR. FAUCI:

I'm Dr. Anthony Fauci. Unfortunately, you've seen a lot of me lately. But thankfully, I'm here to present some good news and I'm excited for the opportunity to shine some light on one of the many young people who have stepped up and helped us throughout a difficult time.

The 24th Annual Webby Awards would like to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world.

As we collectively navigate the severe impact of COVID-19, including the difficult, but critical calls for nationwide social distancing, the Internet has become the lifeblood of people looking for accurate information about the novel coronavirus and the necessary steps to combat it.

Since launching the site on December 29th, Schiffmann's tracking tool has been an invaluable resource that sounded the alarm on the virus and its spread, notably calling attention to its severity long before many global officials.

At a time when the spread of misinformation can be so detrimental to our efforts, the site has provided over 600 million visitors with accurate real-time data. Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and the importance of measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating an essential website to provide real-time data about the virus to people everywhere, it is my great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year.



On May 5, 2020, at 10:31 AM, Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6) wrote:

Lesley – we’ve been discussing this. Can you tell us exactly what would be involved in this? How many minutes would you be looking for Dr. Fauci to speak? Would this be pre-recorded, with Dr. Fauci solo? Or would it be done as a Zoom or something like that, with an interaction between Dr. Fauci and Avi?

From: Billet, Courtney (NIH/NIAID) [E]
Sent: Monday, May 4, 2020 5:31 PM
To: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Lesley – thanks so much for reaching out. Avi is so impressive! I am connecting you with Dr. Fauci’s assistant and scheduler, Patty Conrad, for follow-up.

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Monday, May 4, 2020 5:10 PM
To: Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Fwd: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Courtney,

Hope you are staying well during these uncertain times. I am a Talent Producer for The Webby Awards and had reached out to Dr. Fauci regarding being involved in our “virtual” internet celebration which will showcase the artists, organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

Avi Schiffman is being celebrated as our Person of the Year and we would be honored if Dr Fauci would “virtually” present him his honor. The official letter is below and would love to discuss in more detail when you have a chance to review.

Thank you

Best

Lesley

Begin forwarded message:

From: Lesley Cahill Roy <lesley@lesleycahillroy.com>
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards
Date: May 1, 2020 at 12:13:10 PM EDT
To: [REDACTED] (b) (6)

Hi Dr Fauci

I just wanted to follow up on below regarding Avi and The Webby Awards. Would be wonderful if you could be a part of this moment for him.

Thanks so much

Lesley

On Apr 20, 2020, at 1:57 PM,
lesley lesleycahillroy.com<lesley@lesleycahillroy.com> wrote:

<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>

Dear Dr. Fauci,

I hope you and the family are all safe and healthy during these challenging times. Hailed by The New York Times as "the Internet's highest honor," The Webby Awards has been the premiere award for online excellence for over two decades, honoring the companies and people who have critically shaped digital technology and culture.

This year, due to the impact of the coronavirus The Webby Awards are moving their renowned award show to an online experience. On May 19th, 2020, the 24th Annual Webby Awards will bring together Webby Winners from around the world in an Internet Celebration which will showcase the artists,

organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world. We would be honored if Dr. Fauci would “virtually” present Avi with his award.

As we collectively navigate the severe impact of COVID-19 on the world and late calls for nation-wide social distancing, the Internet has become the lifeblood for people looking for accurate information about the novel coronavirus. Since launching the site on December 29th, Avi Schiffmann’s tracking site was a necessary tool that sounded the alarm on the novel coronavirus and its spread, notably calling attention to its severity long before many global officials. By providing over 100 million visitors with real-time data on the virus’ spread, Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating a website to provide real-time data about the virus to people everywhere, it is our great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. The celebration will highlight the important work Avi and his fellow winners are doing, and will mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci’s presenter speech could be recorded on his phone and we can send you through a script for him to review, edit and details for format and deadline.

This year’s Webby Awards will also take action, the impact of COVID-19 and government responses around the world, has brought the importance of voting into sharp focus. The Webby Awards has partnered with Vote.or and aim to check the voter registration status of 1 million voters in the United States, promoting the importance of voting to help ensure voter turnout this November is the highest it has ever been. This partnership will integrate into all elements of this year’s online celebration.

Our thoughts are with all of you in this difficult time.

Best

Lesley Cahill Roy

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 19:49:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: FW:

unlikely

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Konstantin Vulkov <kv@egoist.bg>
Sent: Tuesday, May 5, 2020 3:42 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Cc: NIAID Ocpstoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)
Subject:

Dear Sir/Madam,

My name is Konstantin Vulkov and I am Program director of the biggest Bulgarian private radio station, Darik radio (www.darikradio.bg). This is a news/talk radio station. I am a regular contributor to Bulgarian National TV as well as several online and print publications, editor-in-chief of egoist.bg as well as editor-in-chief of the biannual Darik-owned publication called Dolce Far Niente.

I am a document photographer as well, focusing mainly on portraits.

I am covering the coronavirus pandemic extensively - visiting COVID-19 units across the country, making my daily radio programme "Mind games", writing stories for our websites www.darikradio.bg, www.dnews.bg and egoist.bg.

It would be an honour if I can make a short telephone interview with Mr. Anthony S. Fauci, M.D.

Please let me know if I can call and make the interview. I promise I won't take more than 10 minutes of Mr. Fauci's time.

Your help is much appreciated.

Best,

Konstantin

Konstantin Vulkov
Program Director
Darik Radio
82, Dondukov blvd.
Sofia 1504
Bulgaria

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 19:48:10 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: AUSTRIA - Try to support - COVID 19 - Strategy

Looks fine.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Tuesday, May 5, 2020 3:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: AUSTRIA - Try to support - COVID 19 - Strategy

Dr. Fauci,

I will respond. Here is what I propose to say (in addition to thanking him). Let me know if you'd change anything:

(b) (5)



Sincerely,

Andrea

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, May 5, 2020 at 10:40 AM
To: "Lerner, Andrea (NIH/NIAID) [E]" (b) (6)
Subject: Fwd: AUSTRIA - Try to support - COVID 19 - Strategy

Not a crazy note. Please respond on my behalf. Thanks

Begin forwarded message:

From: (b) (6)
Date: May 5, 2020 at 8:19:48 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Subject: AUSTRIA - Try to support - COVID 19 - Strategy

Dear – highly respected – Dr. Fauci

Why do I try to childishly support a respected expert and personally highly honored Gentleman like you – Dr. Fauxi ?

Because for me – it is heartbreaking and unbelievably disturbing, what was and is going on in the course of the last 4 months in the USA.


I talk about the USA, that relieved my country - AUSTRIA - 75 years ago from the hell of the NAZI-Regime – with American Lives and Blood.

With all my respect, my hopes, my passion, my tears, my mourning – May Grace and Blessing be with You and the USA.



After running the numbers available on COVID 19 pandemic data – my experiences as an Economist led to following analysis and proposed strategy:

**COVID 19 is a true threat for humans >65 years of age with pre-existing illnesses,
but nearly influenza-like for humans < 65 years of age and humans > 65 years of age without pre-existing illnesses**

AUSTRIA: Deaths by age



Deaths as of 100.000 inhabitants by age




**Germany – Death by age – men and women
– mortality rate in %**

Comparison – Italy and China

Coronavirus Mehr Männer unter den Toten

Die Auswertung des Robert-Koch-Instituts (RKI) basiert auf mehr als 149.000 Coronavirus-Fällen in Deutschland. Unter den mehr als 5000 erfassten Covid-19-Todesfällen finden sich über fast alle Altersgruppen hinweg auffallend mehr Männer als Frauen.



(Anzahl verstorbenen Covid-19-Patienten nach Alter und Geschlecht, Altersgruppen-Einteilung laut RKI, Stand: 23. April 2020)

Grafik: rtl.de / Martin Moczniak • Quelle: RKI



Italien: mehr Covid-19-Tote als in China

Mortalitätsrate in Prozent der Erkrankten

Altersgruppen	ITALIEN	CHINA
0-9	0	0
10-19	0	0,2
20-29	0	0,2
30-39	0,3	0,2
40-49	0,4	0,4
50-59	1,0	1,3
60-69	3,5	3,6
70-79	12,8	8,0
≥ 80	20,2	14,8

Anteil der Verstorbenen über 80 Jahre



Proposed Strategy

1. Keep the virus 100% (totally) away from people older than 60 with pre-existing illnesses

Identify, Testing, Shelter, Preserve from contact with virus, Preserve from Hospitalization and ICU

2. **Minimize possible contact with virus for people older than 60 without pre-existing illnesses**

Identify, Testing, Partial Stay at Home, Social Distancing, , Preserve from Hospitalization and ICU

Once 1 and 2 are warranted:

3. **Handle the rest of the population with care, but keep them going and working – as you would do in an influenza-season**

The critical factor for further intervention is the capacity of the regionally available ICU-capacity

Interventions: Social Distancing, Masks, Testing, Tracing, Stay at home when ill, Quarantine at home when ill

**Respectfully Yours
Gerald Glockenstein**

Mag. Gerald Glockenstein

(b) (6)



From: (b) (6)
Sent: Tue, 5 May 2020 10:47:11 -0400
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: request of interview by Giuseppe Sarcina, corriere della Sera

Please try to get clearance. This is the top newspaper in Italy

Begin forwarded message:

From: Sarcina Giuseppe <gsarcina@rcs.it>
Date: May 5, 2020 at 8:03:29 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: Re: request of interview by Giuseppe Sarcina, corriere della Sera

Inviato da iPhone

Dear Doc. Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera,
the main italian newspaper.
I understood that you are looking at the italian case with great
attention.
I wonder if you can grant me a short interview.
I have sent an email march 21. But then I saw that you spoke with an
other italian newspaper. So I would like to have a chance to have your
voice for our Readers as well. Corriere della Sera is a newspaper based
in Milano, Lombardy, The region most affected by the coronavirus.
Thank you
Warm Regards
Giuseppe Sarcina
Washington dc

(b) (6)

Oggetto: request of interview by Giuseppe Sarcina, corriere della Sera

Dear Doc. Fauci,
this is Giuseppe Sarcina, the us correspondent of Corriere della Sera,
the main italian newspaper.

I understood that you are looking at the italian case with great
attention.

I wonder if you can grant me a short interview.

That would be really helpful for our readers

Thank you

Warm Regards

Giuseppe Sarcina

Washington dc

From: [REDACTED] (b) (6)
Sent: Tue, 5 May 2020 10:43:37 -0400
To: NIAID OD AM
Subject: Fwd: Invitation to Participate in Book Project on COVID-19

Let us discuss. [REDACTED] (b) (5)

Begin forwarded message:

From: Dawinder Sidhu <dss@umbc.edu>
Date: May 5, 2020 at 8:14:12 AM EDT
To: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: Invitation to Participate in Book Project on COVID-19

Dr. Fauci,

I hope this email finds you well. I am a professor at the University of Maryland, an elected term member in the Council on Foreign Relations, and a former fellow at the Supreme Court of the United States.

I am writing because I am preparing a book, tentatively entitled "Rebuilding America: A Blueprint for Post-COVID-19 America," consisting of essays by leading figures on (1) how COVID-19 has impacted their particular field, and (2) how that field should be reimagined in light of the crisis. The essays will reconsider all sectors of society, including law, education, healthcare, fashion, music, etc., and collectively will be the first comprehensive guide for post-coronavirus reconstruction efforts.

I am very hopeful that you may be willing to contribute a short essay on how the current coronavirus has impacted public health policy, and how such policies can and should evolve moving forward.


Only 50 industry leaders are being asked to contribute. Commitments have been secured from an impressive group, including a retired four-star general and a preeminent constitutional scholar. I very much hope you will take part in this innovative project given your historic and unparalleled contributions to the public's understanding of the current crisis.

With respect to logistics, I am hoping to receive commitments from all authors this month, with essays due within one month, and with the

essays available through Amazon's expedited publishing platform roughly one month after that. Each essay should be no more than 1,000 words, and I may offer light edits for the author's final approval. A final note: all proceeds from the sale of the book will be donated.

I am very hopeful that you will give every serious consideration to this invitation, and will lend your voice towards reimagining and revitalizing a new America.

Best,
Dave

Dawinder S. Sidhu
University of Maryland
 (b) (6)

dss@umbc.edu

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 13:00:29 +0000
To: Lipkin, Ian W.
Subject: RE: SARS-CoV-2

Thanks, Ian. I hope that you are well.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lipkin, Ian W. (b) (6)
Sent: Tuesday, May 5, 2020 8:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: SARS-CoV-2

Tony,

(b) (4) This prompted the letter I sent to him last evening to which he responded this morning. I dont expect a response but wanted to keep you updated. We deeply appreciate your efforts in steering and messaging.

All my best,
Ian

Ps. Skoll just invested \$5M in piloting the GIDEoN international capacity building and surveillance network that includes Cliff and others in your intramural team.

Begin forwarded message:

From: ZhuChen (b) (6) >
Subject: Re:SARS-CoV-2
Date: May 5, 2020 at 8:16:23 AM EDT
To: Lipkin, Ian W. (b) (6) >

Dear Ian,

Thank you for your email detailing the

(b) (4)

(b) (4)

(b) (4). I shall keep you informed of any

progress in the coming weeks.

Best,
Zhu

----- Original -----

From: "Lipkin, Ian W." (b) (6);
Date: Tue, May 5, 2020 06:06 AM
To: "ZhuChen" (b) (6) >;
Subject: SARS-CoV-2

Dear Zhu,

The COVID-19 pandemic poses an unprecedented threat not only to global public health but also to economic and political stability. Uncertainty about the origin of COVID-19 pandemic is causing friction worldwide, particularly between China and the United States. There is agreement that the causative agent, SARS-CoV-2 originated in a bat. There is also a high level of confidence that the virus was not deliberately modified in any laboratory. What we do not know is the answers to two questions: (1) whether a precursor virus circulated in the human population before it evolved to become a pandemic virus and (2) whether a precursor virus adapted to humans by first passing through another animal. (b) (4)

(b) (4)



With great affection,
Ian

W. Ian Lipkin, MD
John Snow Professor of Epidemiology and Director
Center for Infection and Immunity
Mailman School of Public Health


Professor of Pathology and Neurology
College of Physicians & Surgeons
Columbia University
722 West 168th Street, 17th Floor
New York, NY 10032

Voice: (b) (6)

Fax: (212) 342-9044

Email: (b) (6)

Administrative Coordinator
(b) (6)



www.cii.columbia.edu

Follow CII on Twitter: CII_Columbia | Facebook: CII.Columbia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 12:40:52 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: VP slides
Attachments: VP brief VRC 5may2020v2.pptx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Monday, May 4, 2020 7:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: VP slides



Tony, here are slides, including changes we discussed. Patty and all have them.
John

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 12:06:24 +0000
To: Harris, Mary (NIH/NIAID) [E]
Subject: RE: Thank you , Dr. Fauci, Thank you so very much!

Mary:

Many thanks for your kind note. It is much appreciated. Stay well.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Mary (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, May 5, 2020 8:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Thank you , Dr. Fauci, Thank you so very much!

Dr. Fauci,

I wanted to personally thank you for being the voice of reason, security, comfort and insight. (b) (6)
(b) (6) As much
as I miss being in the office, I am grateful to say my Director is Dr. Anthony Fauci and share with my family, friends, and church that if you said it, it's gospel. They can bank on it! You have given comfort to my family and myself. You will never know how much! I want you and those who in researchers who are hard at work without much rest but tons of sacrifice including that of your families to find a vaccine, give the Nation a sense of safety and security in this unprecedented time are greatly appreciated. My family, friend and myself are send our prayers for your continued strength. Thank you doesn't seem like enough. I couldn't be prouder to work at NIAID and specifically on the 7th floor of Building 31.

Simply Grateful,

Mary Harris
NIAID Travel Policy Specialist
NIAID Travel Card Coordinator

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 00:37:21 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: CORONA and BACTERIAL SUPERINFECTION
Attachments: 1918 influenza insight- fauci.pdf, ESP el arroz epidemol.pdf, Infection and Immunity-2015-Rynda-Apple-3764.full.pdf, JClinsightco-infection.pdf, lancet.png, Mail Esp.pdf, mail germany 1.pdf, piramide.png, PLEASE FORWARD THIS MESSAGE TO error.pdf, portugal.pdf, Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza - Dr Fauci.pdf, press usa.pdf, Recuperados.pdf, spanish flu 1918 - eng original.pdf, tyska pres mail.pdf, US error message.pdf, Us mail 0408.pdf, WHO-2019-nCoV-clinical-2020.4-eng.pdf, virus piramdie eng.png

Please take a look and decide. Thanks.

From: Ola Melhus [REDACTED] (b) (6)
Sent: Monday, May 4, 2020 12:25 PM
To: [REDACTED] (b) (6) Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: CORONA and BACTERIAL SUPERINFECTION

Dear Doctors,

I don't know if you have got this information.

A truly deadly virus

cannot spread very far. Why? Because people quickly get sick and die. In other words, they cannot spread the virus further, which is a prerequisite for a large spread like corona. Covid-19 has spread throughout the world.

The premise is that it is not very dangerous, it causes mild symptoms for most people, many do not even notice that they were sick. But the virus has different phases in the body, after a while it goes into a resting phase, you feel better, but the virus is still present and can pass on. Covid-19 is an optimally developed virus that spreads rapidly around the world. But if it were really deadly, almost everyone would die.

So far in our 4 billion long history, there have been **no airborne** viruses or bacteria. Yes, in the hollywood movie "outbreak" there was, but it was a movie. Why hasn't it?

If it had existed, this planet would have been a dead planet without life. It would have killed all living. It is possible that there is somewhere else in the universe, but not here on planet Earth. Not now. Remember, this is not the first time a new virus is spreading in the world. What is happening now has happened earlier in our long history.

But people are die you say. Yes, but the virus don't kill them. The virus open a "door" in the cell wall thats allows for bacterias, how always are present, to invade the body and create an aggressiv bacterial superinfection. That's what kills them. See,

1. Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms of Disease.




FIG 1 Common pathways of susceptibility to postinfluenza bacterial superinfections. Early after influenza virus infection, mice show reduced susceptibility to superinfection that is at least in part due to increased production of IL-13. This IL-13-rich environment does not permit IFN- γ production, allowing unaltered phagocytosis and clearance of bacteria. The role for either neutrophils or macrophages (phagocytes) in bacterial clearance early during influenza virus infection has not been fully investigated. Progression of influenza virus infection results in increased susceptibility to secondary infection. Type I IFN (or IL-27) signaling initiated in response to influenza virus infection results in downregulated production of IL-1 β and IL-23 and impaired type 17 immune responses. Inhibition of IL-17 and IL-22 reduces production of antimicrobial peptides. Type I IFN signaling also reduces levels of neutrophil chemoattractants Cxcl1 and Cxcl2 and can induce formation of NETs. IL-27 induced during influenza virus infection further suppresses IL-17 production but stimulates production of regulatory cytokine IL-10, which contributes to increased susceptibility to superinfection, presumably by alteration of the anti-influenza inflammatory response. IAV, influenza A virus infection.

and this reports:

2. Deaths from Bacterial Pneumonia during 1918–19 Influenza Pandemic

3. The 1918 Influenza Pandemic: Insights for the 21st Century

4. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness

5. Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment

6. Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness

How can this happen? How can the doctors be so blind. I have a theory about this and here it comes:

My (b) (6) was a psychologist. May she rest in peace in heaven.

It seems that the corona virus has affected the brain more in a certain group in society, namely politicians, doctors, journalists and other with power and positions in the society. The virus is not dangerous for this group, but it's opens a door in the brain's cell wall that allows it to enter the fear center of the brain.

This door has been closed for many years. We haven't had any major wars and nothing has threatened them. They have felt invulnerable. Convinced of their own superior ability and greatness. Not only can they control the people, they can now control the climate by turning the carbon dioxide tap. If they close it, the temperature drops, if they open it the temperature goes up. They don't know that the sun is 109 times as big as our planet. 109 times. It seems so small when we look up in the sky. They thought they could control everything.

Then came the VIRUS, they receive an abrupt awakening. They get scared. Politicians get sick and die. Doctors die. The brain is attacked by fear virus. They can no longer think clearly and logically. The panic is near, they are reminded of their own mortality. Just like a virus in a computer. It's slows it down and it becomes unusable. That's what happens when a fear virus attacks the brain.

Here where I live, there are panic over 1600 confirmed cases. The television is talking "infected persons" when there is "confirmed laboratory cases". It's two different things. Misleading the people. Why panic over 1 600 infected? Closing all not necessary business, all schools, all except for supermarket, gas station, banks. You can't go out after 5.00 pm. If you do, you get arrested.

Why? They are scared. Because the ruling class is afraid. Everyone with this masks. Doctors crying on television. The President with mask. They are scared. Doctors. Journalists. Polices.

2020. The year when the world got completely crazy.

You have an medical obligation to inform the world about the truth.

Kind regards,

Ola Melhus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 5 May 2020 00:36:13 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Therapeutics and vax
Attachments: NIAID SARS-CoV-2 Tx and Vax overview.docx

Please print out and put in folder labelled "COVID-19 Therapeutics and Vaccines"

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Sent: Monday, May 4, 2020 12:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C]
<(b) (6)>
Subject: Therapeutics and vax

For your Therapeutics discussion later today


From: (b) (6)
Sent: Mon, 4 May 2020 19:52:45 -0400
To: Troye, Olivia EOP/NSC
Cc: Hurst, Natalie R. EOP/OVP; Mascola, John (NIH/VRC) [E]; Graham, Barney (NIH/VRC) [E]; Francis Collins
Subject: Re: Email connecting us

Here they are. Thanks

On May 4, 2020, at 7:46 PM, Troye, Olivia EOP/NSC
(b) (6)

Hi Dr. Fauci,
Per our conversation, sending you a note. I'm copying Natalie who will help get them cleared in.
Thank you!
Olivia

Olivia Troye
Special Advisor to the Vice President for
Homeland Security, Counterterrorism, and North America
Office of the Vice President, National Security Affairs
White House Coronavirus Task Force
O: (b) (6) | M: (b) (6) (Does not receive texts)
(b) (6)





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 21:05:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

Please see me about this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Monday, May 4, 2020 11:18 AM
To: ICDDIR-L@LIST.NIH.GOV
Cc: Parker, Ashley (NIH/OD) [E] (b) (6); Wholley, David (FNIH) [T] (b) (6) >; Melencio, Cheryl (FNIH) [T] (b) (6) >
Subject: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

Dear Colleagues,

As you may be aware, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership has been moving forward rapidly to address the global pandemic. We held our initial ACTIV leadership meeting on April 3rd including, NIH, FDA, BARDA, EMA, and industry heads of research and development. Four working groups were formed out of this meeting to focus on preclinical therapeutics, clinical therapeutics, clinical trial capacity, and vaccines.

Although some ICs have representatives participating in the working groups, we recognize there is a need to keep everyone looped in to the various activities and progress of the partnership, particularly in view of all of the concurrent IC projects about COVID-19. The ACTIV working groups will be delivering their second report to the **ACTIV Leadership Group on Wednesday, May 6, from 3:30-5:00pm**. I am writing to invite the ICs to listen-in on this meeting. There will be a lot to cover during the meeting and the members of the Leadership Group will be asking the questions. But to give a chance for us NIHers to

discuss what has been presented, I am scheduling a separate ICD call for 5:05-5:30pm, immediately following the ACTIV leadership meeting.

If you are available to take part, please send your responses to David Wholley and Cheryl Melencio of FNIH (cc'd here) by noon tomorrow, May 5th. Once you confirm your attendance, Cheryl will send you a calendar invite for both the ACTIV leadership meeting and the ICD follow-up call.

Best regards,
Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 15:28:08 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Need your help Covid-19 CAS-10685

I do not know this person. We should refer him to Brett Giroir.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Monday, May 4, 2020 10:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Need your help Covid-19 CAS-10685

Do you know this person?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept

liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Kara (NIH/NIAID) [E] (b) (6) >
Sent: Friday, May 1, 2020 8:38 AM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6) >
Cc: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Haskins, Melinda (NIH/NIAID) [E] (b) (6) >
Subject: FW: Need your help Covid-19 CAS-10685

Hi, Patty –

This individual states that he previously worked with Dr. Fauci and that he knows him. Please let me know if you would like Public Inquiries to handle.

Thanks,
Kara

From: Ray Rosa (b) (6) >
Sent: Thursday, April 30, 2020 5:58 PM
To: NIAID Ocpstoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>
Subject: Need your help Covid-19

I am working with a group of physicians whom need your guidance on Serum Covid-19 tests. I need someone to call me so I can ask specific questions. I worked with Dr Fauci back in 1998 when I was in the Air Force. So he does know me. Ray Rosa is the name. Can you please call me.

(b) (6) cell

Send from AOL Mobile Mail
Get the new AOL app: mail.mobile.aol.com

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 14:00:23 +0000
To: NIAID OD AM
Subject: FW: inquiry

Another one that he will probably want to do.

From: Augustine M. K. Choi <[REDACTED]> (b) (6)
Sent: Monday, May 4, 2020 9:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED]> (b) (6) >
Subject: inquiry

Hi Tony,

I can only imagine your schedule. Thank you for all you are doing for the country in our fight against this virus.

Weill Cornell would like to invite you for a 3 min remarks to the Class of 2020 at their upcoming graduation if your schedule allows. The virtual graduation is on May 28th. We can tape your remarks at any time which fits your schedule, from now or up to right before May 28.

If you able to accept this invitation, please let me know. If not, totally understandable and we would love to have you back again after covid subsides.

Thanks again!

Augustine M.K. Choi, M.D.
Stephen and Suzanne Weiss Dean, Weill Cornell Medicine
Provost for Medical Affairs, Cornell University

Weill Cornell Medicine
1300 York Avenue, Suite F-113 Box 83 | New York, NY 10065
Telephone: 212-746-6005
Fax: 212-746-8424
Email: amc2056@med.cornell.edu

From: Anthony Fauci <[REDACTED]> (b) (6)
Date: Monday, March 30, 2020 at 12:19 PM
To: Augustine Choi <[REDACTED]> (b) (6)
Subject: [EXTERNAL] RE: all wearing masks

My work with the Coronavirus Task Force and the large volume of incoming emails precludes me or my staff from answering each individual message. I would encourage you to visit www.coronavirus.gov for the latest information and guidance related to COVID-19.

Thank you, and best regards.

Anthony S. Fauci, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 12:28:04 +0000
To: Corey, Larry
Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

As an FYI for the 9:00 AM meeting.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dolsten, Mikael (b) (6) >
Sent: Monday, May 4, 2020 8:15 AM
To: Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Mascola, John (NIH/VRC) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >; Lowy, Douglas (NIH/NCI) [E] (b) (6) >; Jansen, Kathrin (b) (6) >
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis
Thanks for the response

We appreciate the federal initiative and opportunity to influence it's design . I know Kathrin Jansen (ccd here) from PFE is working w the team on this.

(b) (4)
(b) (4) It's great to be collaborating w NIH-FDA for the best of our nation and global health .

In the master protocol , I hope the working committee is discussing (b) (5)
(b) (5)

(b) (5)

These are just two examples we can discuss on Wednesday in the leadership meeting if time permits .

(b) (5)

I look forward to the meeting

Best
Mikael
Sent from my iPhone

On May 4, 2020, at 04:26, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Hi Mikael,

Wow, sounds like you are making fantastic progress with the vaccine program, and we would certainly not want to do anything to slow you down! I understand that you are evaluating several mRNA formats with BioNTech. If one of those turned out to be ready for phase II/III in late June, we would be most interested in the possibility of including that in the master protocol. Please keep Tony and me in touch with Pfizer's progress, including which mRNA format you choose to move into advanced development.

Hope to hear your voice at the ACTIV Leadership Group meeting on Wednesday. There will be a lot to talk about!

Best, Francis

From: Dolsten, Mikael [REDACTED] (b) (6) >

Sent: Sunday, May 3, 2020 6:26 PM

To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >

Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below



I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice
Mikael

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E]

[REDACTED] (b) (6) > wrote:

Mats

Hi Mikael,

Thanks for your note and this update on exciting progress on several fronts. ACTIV is moving forward with gratifying speed and commitment. With regard to vaccines, tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase II/III trial with adaptive design, multiple arms, and a shared placebo arm, aiming to launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and JnJ vaccines are likely to be included – might Pfizer also join?

[REDACTED] (b) (4) – I trust that compound is on the list of therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing? They are supposed to put forward a tentative list for the Wednesday Leadership Group meeting. Ditto with the (b) (4) option!

Looking forward to catching up soon!

Best, Francis

From: Dolsten, Mikael [REDACTED] (b) (6) >
Sent: Sunday, May 3, 2020 12:06 PM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

I trust you are well but likely working too many hours as we all experience in the difficult Covid times.

In the vaccine space we have progressed rapidly and are already in phase 1/2 studies dose escalation phase testing multiple format of mRNA vaccine . Key for us is [REDACTED] (b) (4) .

In the anti-viral areas we are [REDACTED] (b) (4)

[REDACTED]

We also want to start [REDACTED] (b) (4)

[REDACTED]

(b) (4)

How are things going w ACTIV.
Any issues to discuss ?

I hope our PFE representatives in ACTIV are helping out well

Pls let me know if there is anything particular to discuss or I can help you with

Best personal regards
Mikael

Sent from my iPhone

On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E]

(b) (6) > wrote:

Hi Morten,

Thanks for your note. It would be great to have this connection – but let me suggest that you start with David Wholley (cc'd here), as he oversees all four of the ACTIV working groups. Joe is the program lead for the group on preclinical therapeutics/repurposing.

Best, Francis

From: Sogaard, Morten (b) (6)
Sent: Sunday, May 3, 2020 10:46 AM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Dolsten, Mikael (b) (6); Prof Trevor M Jones CBE FMedSci (b) (6); Sogaard, Morten (b) (6) >
Subject: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis,

I hope you are having a good weekend.

Quick question: Would you be OK if I/we reached out to Joe Menetski, who I understand leads many of the ACTIV efforts. We have come to know Joe very well as a great collaborator on the AMP gene therapy initiative and It would be very easy I think working informally with Joe to look a bit more under the hood and identify/ map opportunities for alignment with the other initiatives.

All the Best,
Morten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 10:53:14 +0000
To: Haskins, Melinda (NIH/NIAID) [E]
Subject: RE: EOP/OMB Alert: May Hearing Guidance

What does this mean for the May 12 Senate Hearing?

From: Haskins, Melinda (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Monday, May 4, 2020 6:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: EOP/OMB Alert: May Hearing Guidance

I have highlighted in yellow the fundamentals of the OMB guidance below.

Melinda


From: Hallett, Adrienne (NIH/OD) [E] [REDACTED] (b) (6)>
Sent: Sunday, May 3, 2020 9:54 PM
To: OD-OLPA-Leg Contacts <OD-OLPA-LegContacts@OD.NIH.GOV>
Subject: Fwd: May Hearing Guidance

FYI. New OMB hearing guidance.

From: Yaworske, Jason A. EOP/OMB [REDACTED] (b) (6)>
Sent: Sunday, May 3, 2020 9:06 PM
Cc: Ueland, Eric M. EOP/WHO <[REDACTED] (b) (6)>; Hodgson, Christopher (ovp.eop.gov) <[REDACTED] (b) (6)>
Subject: May Hearing Guidance
Importance: High

Agency legislative affairs teams,

[REDACTED] (b)(5) - PCP



Thank you, and please let us know if you have any questions.

Jason

Jason Yaworske
Associate Director for Legislative Affairs
Office of Management and Budget

(b) (6) (o)

(b) (6) (c)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 May 2020 00:50:18 +0000
To: Collins, Francis (NIH/OD) [E]; Mascola, John (NIH/VRC) [E]; Lane, Cliff (NIH/NIAID) [E]
Cc: Tabak, Lawrence (NIH/OD) [E]; Parker, Ashley (NIH/OD) [E]
Subject: RE: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

We need to find out precisely what he is talking about when he says “vaccine formats” and “refined formats”. I really do not know what he is talking about. (b) (4), (b) (5)

John/Cliff:

Let us discuss this at our morning meeting.

Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Sunday, May 3, 2020 8:03 PM
To: Mascola, John (NIH/VRC) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Tabak, Lawrence (NIH/OD) [E] (b) (6); Parker, Ashley (NIH/OD) [E] (b) (6)
Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi John, Cliff, and Tony,

See note below, where Mikael Dolsten indicates Pfizer is planning to (b) (4). He intends to discuss our master protocol possibility with Kathrin Jensen. I am not quite sure what he means by “several vaccine formats”.

Does this timetable sound realistic?

Any suggestion about a response?

Francis


From: Dolsten, Mikael (b) (6)
Sent: Sunday, May 3, 2020 6:26 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)

Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below



I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice
Mikael

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E] <[redacted]> (b) (6) wrote:
Mats

Hi Mikael,

Thanks for your note and this update on exciting progress on several fronts. ACTIV is moving forward with gratifying speed and commitment. With regard to vaccines, tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase II/III trial with adaptive design, multiple arms, and a shared placebo arm, aiming to launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and JnJ vaccines are likely to be included – might Pfizer also join?

(b) (4)– I trust that compound is on the list of therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing? They are supposed to put forward a tentative list for the Wednesday Leadership Group meeting. Ditto with the (b) (4) option!

Looking forward to catching up soon!

Best, Francis

From: Dolsten, Mikael (b) (6)
Sent: Sunday, May 3, 2020 12:06 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

I trust you are well but likely working too many hours as we all experience in the difficult Covid times.

In the vaccine space we (b) (4)
(b) (4)
(b) (4)

In the anti-viral areas we are (b) (4)
(b) (4)

(b) (4)

How are things going w ACTIV.
Any issues to discuss ?

I hope our PFE representatives in ACTIV are helping out well

Pls let me know if there is anything particular to discuss or I can help you with

Best personal regards
Mikael

Sent from my iPhone

On May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) wrote:

Hi Morten,

Thanks for your note. It would be great to have this connection – but let me suggest that you start with David Wholley (cc'd here), as he oversees all four of the ACTIV working groups. Joe is the program lead for the group on preclinical therapeutics/repurposing.

Best, Francis

From: Sogaard, Morten [REDACTED] (b) (6) >
Sent: Sunday, May 3, 2020 10:46 AM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >
Cc: Dolsten, Mikael [REDACTED] (b) (6); Prof Trevor M Jones CBE FMedSci [REDACTED] (b) (6); Sogaard, Morten [REDACTED] (b) (6)
Subject: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Francis,

I hope you are having a good weekend.

Quick question: Would you be OK if I/we reached out to Joe Menetski, who I understand leads many of the ACTIV efforts. We have come to know Joe very well as a great collaborator on the AMP gene therapy initiative and It would be very easy I think working informally with Joe to look a bit more under the hood and identify/ map opportunities for alignment with the other initiatives.

All the Best,
Morten

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:45:43 +0000
To: Greg Folkers ([REDACTED] (b) (6)); Doepel, Laurie (NIH/NIAID) [E]
Subject: Pitt and INC
Attachments: Commencement Remarks, generic 30-sec for UPitt and UNC SOM, - FINAL - for 5-08-2020 (videos).docx

See attachment with remarks for UPitt and UNC . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:28:33 +0000
To: Greg Folkers (b) (6); Doepel, Laurie (NIH/NIAID) [E]
Subject: USUHS
Attachments: Commencement Remarks, USUHS 2-min -FINAL - for 5-16-2020 (Video).docx

See attachment with USUHS remarks . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 21:21:04 +0000
To: Greg Folkers (b) (6); Doepel, Laurie (NIH/NIAID) [E]
Subject: AMA
Attachments: Commencement Remarks, AMA 3-min - FINAL - for May 2020 (Video).docx

See attachment with AMA remarks . I have left the tracked changes showing so that you can see what I have done. Please accept these and then proof it. It is now marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 20:58:32 +0000
To: Doepel, Laurie (NIH/NIAID) [E]; Greg Folkers (b) (6)
Subject: UCSF
Attachments: Commencement Remarks, UCSF SOM - FINAL - for May 2020 (Video).docx

Greg/Laurie:

I am attaching the UCSF 3 minute talk. I labeled it as "FINAL" and it is in the OD folder. However, I have left in the tracked changes for you to see what I did. Please accept the changes and then go over it one last time. I like it the way it is and so please no trivial corrections.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 20:11:08 +0000
To: Doepel, Laurie (NIH/NIAID) [E]; Greg Folkers ([REDACTED] (b) (6))
Subject: Holy Cross
Attachments: Commencement Remarks, Holy Cross - FINAL - for 05-22-2020 (video).docx

The Holy Cross video script is in the OD File marked as "FINAL". I have left the tracked changes showing so that you will know what I have done. Please accept the changes and take a final look. I am also attaching for your look.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 18:34:28 +0000
To: Tromberg, Bruce (NIH/NIBIB) [E]; 'Sharpless, Ned
(b) (6)'
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: 2 quick points

Thanks, Bruce.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tromberg, Bruce (NIH/NIBIB) [E] (b) (6)>
Sent: Sunday, May 3, 2020 2:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); 'Sharpless, Ned
(b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: Re: 2 quick points

Hi Tony,

Thanks! Hope you are doing well.

This is basically exactly what we are working to facilitate with our RADx and digital health (app) platform initiatives...greatly expanding testing and creating a digital backbone to provide people with ways to access tests and interpret results. For expanding testing platforms, see <https://www.nibib.nih.gov/news-events/newsroom/nih-mobilizes-national-innovation-initiative-covid-19-diagnostics> We have >700 applications that have been started in just a few days. For the digital health (e.g. app) platform we've put a lot of thought into the design and are hoping a contractor will be able to launch a pilot study of healthcare workers soon. Ned and I plan on issuing additional calls in this area with multiple institutes as stakeholders in the coming weeks.

Best,
Bruce

Bruce J. Tromberg, Ph.D.

Director
National Institute of Biomedical Imaging and Bioengineering
National Institutes of Health
Building 31, Room 1C14
Bethesda, MD 20892-2281
(b) (6)
301-480-0679 - FAX
(b) (6)
<http://www.nibib.nih.gov>

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, May 3, 2020 at 1:55 PM
To: "Sharpless, Ned" (b) (6)
"Tromberg, Bruce (NIH/NIBIB) [E]" (b) (6)>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Subject: FW: 2 quick points

Ned/Bruce:

I thought that I would pass this on to you in case you have interest. Thanks.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen (b) (6)>
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview [REDACTED] (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland ([REDACTED] (b) (6) [REDACTED]). As his email says, [REDACTED] (b) (6) with Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 [REDACTED] (b) (4) [REDACTED]. It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out [REDACTED] (b) (6) [REDACTED], and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto:[REDACTED] (b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: [REDACTED] (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up [REDACTED] (b) (6) but I'm writing because it might yet bring at least the two of us together.

[REDACTED] (b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:56:39 +0000
To: NIAID OD AM
Subject: RE: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

????? Who is this person?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6) > On Behalf Of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sunday, May 3, 2020 1:55 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

From: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>
Sent: Friday, May 1, 2020 12:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby Awards

Hi Dr Fauci

I just wanted to follow up on below regarding Avi and The Webby Awards. Would be wonderful if you could be a part of this moment for him.

Thanks so much

Lesley

On Apr 20, 2020, at 1:57 PM, lesley lesleycahillroy.com <lesley@lesleycahillroy.com> wrote:

<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>

Dear Dr. Fauci,

I hope you and the family are all safe and healthy during these challenging times. Hailed by The New York Times as “the Internet’s highest honor,” The Webby Awards has been the premiere award for online excellence for over two decades, honoring the companies and people who have critically shaped digital technology and culture.

This year, due to the impact of the coronavirus The Webby Awards are moving their renowned award show to an online experience. On May 19th, 2020, the 24th Annual Webby Awards will bring together Webby Winners from around the world in an Internet Celebration which will showcase the artists, organizations, and creators using their platforms to imagine a better tomorrow through information, education, movement, comedy, all while inspiring audiences to take action to enact positive change.

The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Person of the Year to recognize his creation of ncov2019.live to track the spread of COVID-19 across the world. We would be honored if Dr. Fauci would “virtually” present Avi with his award.

As we collectively navigate the severe impact of COVID-19 on the world and late calls for nation-wide social distancing, the Internet has become the lifeblood for people looking for accurate information about the novel coronavirus. Since launching the site on December 29th, Avi Schiffmann’s tracking site was a necessary tool that sounded the alarm on the novel coronavirus and its spread, notably calling attention to its severity long before many global officials. By providing over 100 million visitors with real-time data on the virus’ spread, Schiffmann has helped people around the globe understand COVID-19 and the necessity of upgrades to current health care systems and measures to flatten the curve.

For having the foresight to track the global spread of COVID-19 and for creating a website to provide real-time data about the virus to people everywhere, it is our great privilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. The celebration will highlight the important work Avi and his fellow winners are doing, and will mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci's presenter speech could be recorded on his phone and we can send you through a script for him to review, edit and details for format and deadline.

This year’s Webby Awards will also take action, the impact of COVID-19 and government responses around the world, has brought the importance of voting into sharp focus. The

Webby Awards has partnered with Vote.or and aim to check the voter registration status of 1 million voters in the United States, promoting the importance of voting to help ensure voter turnout this November is the highest it has ever been. This partnership will integrate into all elements of this year's online celebration.

Our thoughts are with all of you in this difficult time.

Best

Lesley Cahill Roy

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:55:14 +0000
To: 'Sharpless, Ned [REDACTED] (b) (6)'; Tromberg, Bruce (NIH/NIBIB) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 2 quick points
Attachments: covid contact tracing.pdf

Ned/Bruce:

I thought that I would pass this on to you in case you have interest. Thanks.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen [REDACTED] (b) (6)
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview [REDACTED] (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland [REDACTED] (b) (6) [REDACTED]. As his email says [REDACTED] (b) (6) Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 [REDACTED] (b) (4) [REDACTED]. It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time

to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) (6) and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto:(b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up (b) (6) but I'm writing because it might yet bring at least the two of us together.

(b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:53:55 +0000
To: Eric Ottesen
Subject: RE: 2 quick points

Eric:

Thanks for your note. No problem. I will forward this to people here at NIH who are pursuing such approaches. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen (b) (6)>
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland (b) (6). As his email says, (b) (6) Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 (b) (4). It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) (6), and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto:(b) (6)]
Sent: Thursday, April 30, 2020 6:52 PM
To: (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up (b) (6) but I'm writing because it might yet bring at least the two of us together.

(b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201
(b) (6)

From: Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:52:37 +0000
To: NIAID OD AM
Subject: FW: INVITE- American College of Cardiology
Importance: High

From: Kim, Jonathan Ho-Youn (b) (6)
Sent: Friday, May 1, 2020 3:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Ryan Meyer (b) (6) Rcbyn Snyder (b) (6)
Subject: Re: INVITE- American College of Cardiology
Importance: High

Dr. Fauci- Of course, I appreciate how busy you are, so just reaching out again on behalf of the American College of Cardiology as noted below. We were hopeful we could steal just an hour of your time in June for an important discussion on COVID-19 and exercise training. This is part of a virtual agenda for one of our national conferences (Care of the Athletic Heart) with outreach around the world given this is a part of the ACC educational platform.

We hope this is something you have the bandwidth for, and simply appreciate your consideration. I hope to hear from you and thank you for all your service once again.

My best, Jonathan Kim

Jonathan H. Kim MD, MSc, FACC
Chief of Sports Cardiology
Department of Medicine, Division of Cardiology
Department of Orthopedics
Emory University
Adjunct Assistant Professor
Division of Applied Physiology
Georgia Institute of Technology
Team Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, Atlanta Braves, and Atlanta Dream
Office Phone: (b) (6)
Research Profile: <http://medicine.emory.edu/cardiology/emory-first-faculty-directory/profile.html?f=JKIM10>
Email: (b) (6)

From: Kim, Jonathan Ho-Youn
Sent: Thursday, April 16, 2020 3:46 PM

To: [REDACTED] (b) (6)
Cc: Ryan Meyer [REDACTED] (b) (6)>; Rcbyn Snyder [REDACTED] (b) (6)>
Subject: INVITE- American College of Cardiology

Dr. Fauci-

On behalf of the American College of Cardiology (ACC), first I would like to thank you for your tremendous service throughout your incredible career and certainly during these present and challenging times. We are indebted to your service and thankful everyday we have you to help guide public health measures through the COVID-19 pandemic.

I am a member of the Sports and Exercise Council for the ACC and the Course Chair for our annual ACC Care of the Athletic Heart Conference. Originally scheduled June 18-20, 2020 at ACC Heart House in Washington DC. I am also faculty at Emory University and direct our sports cardiology program in Atlanta.

Of course, we have made the difficult decision to cancel our live meeting in June, but myself along with the staff at ACC are working very hard transitioning the course to a virtual course and agenda. This course will be a much shorter version and the agenda will all be pre-recorded and distributed as a 'live simulated version' on June 20, 2020.

With the impact of COVID-19 on all aspects of life and society, in our academic world of sports cardiology, we are dealing with how COVID has impacted exercise and athletes. As you can imagine, there are a multitude of different issues and questions that colleagues are raising.

One new session for our virtual agenda that we think will generate a lot of interest and is of high importance will be a panel discussion on sports, exercise, and COVID-19. We would like to get additional expertise on the panel from the ID/public health and Sports Medicine arenas, in addition to sports cardiology. Of course, there is no one that carries the expertise you do from the ID and public health perspective and we would be extremely honored if you could be a part of this one session and join our faculty for the course.

Before getting into more details and a formal invite from the ACC, I wanted to first see if you had the bandwidth for this. Understanding you are as busy, if not busier, than anyone in the world right now. This session would be pre-recorded and we would certainly work to be flexible with anytime you had for this in early June to record.

I hope this is something that could work- again we would be honored to host you virtually.

Many thanks for considering, and hope to hear from you soon. Best, Jonathan Kim

Jonathan H. Kim MD, MSc, FACC
Chief of Sports Cardiology

Department of Medicine, Division of Cardiology
Department of Orthopedics
Emory University
Adjunct Assistant Professor
Division of Applied Physiology
Georgia Institute of Technology
Team Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, Atlanta Braves, and Atlanta Dream
Office Phone: (b) (6)
Research Profile: <http://medicine.emory.edu/cardiology/emory-first-faculty-directory/profile.html?f=JKIM10>
Email: (b) (6)

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:50:45 +0000
To: Jon LaPook
Subject: RE: Today's segment on CBS Sunday Morning

Jon:

Terrific piece on "No time to abandon science"! Keep up this great work. We need to stay on course.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)
Sent: Sunday, May 3, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Today's segment on CBS Sunday Morning

Dear Tony,

I hope (though would not bet my life that) you are getting at least a modicum of down time today.

Here's a link to the segment I told you about. No commercial!

<https://www.youtube.com/watch?v=0jCohlBICg0>


[<http://img.youtube.com/vi/0jCohlBICg0/0.jpg>]<<https://www.youtube.com/watch?v=0jCohlBICg0>>

Dr. Jon LaPook: No time to abandon science - YouTube<<https://www.youtube.com/watch?v=0jCohlBICg0>>
www.youtube.com

As we reach a point in the COVID-19 pandemic when some states are tempted to open sooner than health experts say they should, Dr. Jon LaPook notes that this ...

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS Evening News Professor of Medicine NYU Langone Health





From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:23:12 +0000
To: Paola Dama
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: White House Coronavirus Task Force

Dr. Dama:

Thank you for your note. I am attaching a slide of the members of the USA Task Force and as you can see, Dr. Antonio Giordano is not a member.

Best regards,
A.S. Fauci

White House Coronavirus Task Force – Announced Jan. 29, 2020

Chair: VP Mike Pence

Response Coordinator: Deborah Birx

- | | |
|----------------------|---------------------|
| ■ Jerome Adams | ■ Stephen Hahn |
| ■ Alex Azar | ■ Derek Kan |
| ■ Stephen Biegun | ■ Larry Kudlow |
| ■ Robert Blair | ■ Chris Liddell |
| ■ Ben Carson | ■ Steven Mnuchin |
| ■ Ken Cuccinelli | ■ Robert O'Brien |
| ■ Kelvin Droegemeier | ■ Matthew Pottinger |
| ■ Anthony Fauci | ■ Robert Redfield |
| ■ Joe Grogan | ■ Joel Szabat |



- | |
|-----------------|
| ■ Seema Verma |
| ■ Robert Wilkie |

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paola Dama [REDACTED] (b) (6) >
Sent: Sunday, May 3, 2020 10:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: White House Coronavirus Task Force

Dear Dr. Fauci,

I hope to find you well with this email.
I take the liberty to write you because I have some concern about the misinformation that can discredit your task and honors.
On many occasions in tv and press, Antonio Giordano, Director of Sbarro Institute in Philadelphia, Keeps saying that he is a member of the USA Task Force.
I'm wondering if it's true.

I work in UK, but I'm originally from Naples (Italy).
I held my PhD in Carlo Croce's lab at OSU and I specialized in immunotherapy at University of Chicago.
Currently I'm a research fellow at University of Sussex.

I apologize if you find this email inopportune, the time is unfortunate, I grant you.
I don't like the idea that some people might take advantage of this very unpleasant moment for all the world.
So I wish that I made a mistake this time.

I'm also wondering if you are willing to release a brief interview.
I stand with you and USA that I miss very much

I really appreciate your time
Thank you
Kind Regards
Ciao ☺

Paola Dama, Ph D
Molecular Oncology and Pharmacology

University of Sussex
School of Life Sciences
John Maynard Smith (JMS) Building
Room 4B13
Falmer, Brighton BN1 9QG

cell. [REDACTED] (b) (6) (Italia) / [REDACTED] (b) (6) (USA)
[REDACTED] (b) (6)

Email: [REDACTED] (b) (6)
Skype: [REDACTED] (b) (6)
website www.taskforcepandora.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 15:44:23 +0000
To: [REDACTED] (b) (6)
[REDACTED]
Subject: Great photo of Mommy and me in this article

<https://www.usatoday.com/story/news/nation/2020/05/03/coronavirus-white-house-expert-dr-anthony-fauci-americans-trust/3042991001/>

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] (b) (6)
Sent: Sun, 3 May 2020 10:30:04 -0400
To: Collins, Francis (NIH/OD) [E]
Cc: Mascola, John (NIH/VRC) [E]; Lane, Cliff (NIH/NIAID) [E]; Wholley, David (FNIH) [T]; Tabak, Lawrence (NIH/OD) [E]; Denny, Joshua (NIH/OD) [E]; Gebo, Kelly (NIH/OD) [G]; Lowy, Douglas (NIH/NCI) [E]; Devaney, Stephanie (NIH/OD) [E]; Adam, Stacey (FNIH) [T]; Santos, Michael (FNIH) [T]; Freire, Maria (FNIH) [T]
Subject: Re: crazy idea

[REDACTED] (b) (5)

On May 3, 2020, at 9:47 AM, Collins, Francis (NIH/OD) [E]
[REDACTED] (b) (6) >wrote:

Hi John, Cliff, and Tony,

As we contemplate ways to stand up a master protocol that could enroll 50 – 100K participants in a multi-arm COVID-19 trial this summer, I wondered if [REDACTED] (b) (5)

[REDACTED]

See below - [REDACTED] (b) (5). What do you think?

Francis

From: Denny, Joshua (NIH/OD) [E] [REDACTED] (b) (6) >
Sent: Saturday, May 2, 2020 11:22 PM
To: Collins, Francis (NIH/OD) [E] < [REDACTED] (b) (6) >
Cc: Tabak, Lawrence (NIH/OD) [E] [REDACTED] (b) (6) >
Subject: Re: crazy idea

Hi Francis,

This is exciting to hear! Fabulous to hear we may be approaching such a trial. [REDACTED] (b) (5)

[REDACTED]

(b) (5)

A large rectangular area of the document is completely redacted with a solid grey fill.

Best,
Josh

Sent from my iPhone

On May 2, 2020, at 8:34 PM, Collins, Francis (NIH/OD) [E]

(b) (6) >wrote:


Hi Josh,

Developments over the last week (b) (5)

(b) (5)

(b) (5)

(b) (5)

A large rectangular area of the document is completely redacted with a solid grey fill.

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 12:31:13 +0000
To: Handley, Gray (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: form Jorge Perez IPK Cuba

Thanks.

From: Handley, Gray (NIH/NIAID) [E] (b) (6)
Sent: Saturday, May 2, 2020 11:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: form Jorge Perez IPK Cuba

Will send a reply tomorrow morning.

I have spoken to State Department and have approved response. Someone will listen in.

Will copy you.

Gray

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, May 2, 2020 3:18 PM
To: Handley, Gray (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: FW: form Jorge Perez IPK Cuba

Gray:

Would you please handle this.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any

other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pérez Avila, Jorge <(b) (6)>
Sent: Friday, May 1, 2020 12:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: form Jorge Perez IPK Cuba

Dear Dr. Fauci

Hello from Cuba.

Have been a long time we haven't been in touch.

Now the whole world is facing a new epidemic and in Cuba we are working in order to controlling. We will like to re-new our contact regarding this disease Covid 19, we prepare a telephone conference in order to exchange ideas to have a better understanding to control the epidemic. This conference will be held from Cuba next tuesday 05/05/2020 at 4:30pm Cuban time. In clouse I am sending the topics. We will like to have you and Dr. Handley in this activity if it is possible to attend this conference. If you are in agreement we will like to know by answering this email and them we will you any other detail.

If you have any other person to contact in order to participate will be helpfull for us.

Waiting for your answer.

Dr. Jorge Perez
IPK
Cuba

Preliminary program

Objectives:

- Updating COVID-19 situation at global, regional and mainly in Cuba and USA
- To sharing data of how our two countries are facing this emergency including research studies, etc

Topics for the discussion:

- The main strategies that both countries are developing to face COVID-19.
- Diagnostic strategy
- Clinical management in adults and children
- Innovative Cuban biotechnology products incorporated into the treatment models used in the different stages of treatment
- Some other research studies
- Discussion

Events and courses at the following address:

<http://instituciones.sld.cu/ipk/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 20:17:31 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE:

Thanks

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, May 2, 2020 4:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Erbeling, Emily (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE:

Hi,

I already reached out to Dr. Bolognesi and some of us in Program have a call scheduled with him to discuss this proposal.

I will let you know the outcome.

Kind regards,
Cristina

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, May 2, 2020 3:39 PM
To: Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >
Cc: Erbeling, Emily (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: RE:
Importance: High

Cristina:

It would be a good idea for you to show this to a couple of other NIAID people for their opinion, and then out of courtesy to get back to Dr. Bolognesi one way or another.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cassetti, Cristina (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, April 30, 2020 11:36 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] (b) (6)>
Subject: RE:

Dear Dr. Fauci,

I reviewed this proposal (b) (5)
(b) (5), (b) (4)



(b) (5) informative
to discuss the project directly with them. Would you like for me to put together a small group at NIAID (with reps from DMID and DAIDS) to talk with Dr. Bolognesi and his colleagues?

Kind regards,

Cristina

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Thursday, April 30, 2020 7:58 PM
To: Cassetti, Cristina (NIH/NIAID) [E] <(b) (6)>
Cc: Erbeding, Emily (NIH/NIAID) [E] <(b) (6)>
Subject: FW:
Importance: High

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.

Thanks,

Tony

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6)

Sent: Monday, April 27, 2020 6:09 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C]

<(b) (6)>

Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." (b) (6)
Date: Monday, April 27, 2020 at 2:53 PM
To: "Matthias Gromeier, M.D." (b) (6) >
Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 19:08:58 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Please take a look at this and respond if appropriate.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Idonae Lovetrue (b) (6) >
Sent: Friday, May 1, 2020 2:25 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Beigel, John (NIH) [E] (b) (6); Booth, Mason (NIH/NIAID) [C]
(b) (6) Kim, Sonnie (NIH/NIAID) [E] (b) (6)
Subject: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2 viral load

Dear Dr. Fauci,

I'd like to share with you that the recent clinical trial results on remdesivir have validated our prediction of the remdesivir-specific post-treatment viral rebound in human COVID-19 patients. More details can be found in our official announcement <https://bit.ly/RRemdesivir>.

This prediction of remdesivir's clinical efficacy on viral load made on Feb. 23 2020 (b) (4)

(b) (4)

(b) (4)

We appreciate and respect all the efforts your have made towards the COVID-19 pandemic.

Best regards,
Idonae

Idonae Lovetrue | CEO, Demiurge Technologies AG, Switzerland

www.demiurge.technology

This email and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this email (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately and permanently delete the original and any copies of this email and any attachments thereto. This email is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. While some information used on this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 19:00:06 +0000
To: Fetalvo, Ninio J. EOP/OVP
Subject: RE: Back to CMS

Ninio:

Thanks for all your good work in the White House. Stay safe and well.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fetalvo, Ninio J. EOP/OVP (b) (6)
Sent: Friday, May 1, 2020 3:12 PM
To: (b) (6); Fetalvo, Ninio (CMS/OC) (b) (6)
Subject: Back to CMS

All,

Today is my last day on detail to the Office of the Vice President. I am heading back to CMS to continue supporting the Trump Administration's response to the coronavirus. It has been an incredible honor serving the Vice President and the Coronavirus Task Force, and a pleasure working alongside all of you. I look forward to our ongoing work together.

Best,
Ninio

—

Ninio J.H. Fetalvo

Personal: (b) (6) | (b) (6)
CMS: (b) (6) | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:27:23 +0000
To: Johnson, Martin S. (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; NIAID OCGR Leg; McGowan, John J. (NIH/NIAID) [E]; Erbelding, Emily (NIH/NIAID) [E]; Lane, Cliff (NIH/NIAID) [E]; Rotrosen, Daniel (NIH/NIAID) [E]; Crum, Wayne (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Cc: Eisinger, Robert (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Doepel, Laurie (NIH/NIAID) [E]; Gilles, Sharon (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Law, Kim (NIH/NIAID) [E]; Lee, Kun-Lin (NIH/NIAID) [E]; Bushar, Nicholas (NIH/NIAID) [E]; Schneider, Johanna (NIH/NIAID) [E]
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Thanks, Martin.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Martin S. (NIH/NIAID) [E] (b) (6)
Sent: Friday, May 1, 2020 7:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] <wcrum@niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6) v>;

Schneider, Johanna (NIH/NIAID) [E] (b) (6)

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Tony,

YTD spending is \$110.8M, increasing \$24.1M from last week.

Spending driven by implementation of 3 epidemiological studies, ramp up of resources necessary for vaccine candidate testing and vaccine candidate development.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, April 24, 2020 7:11 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)

Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] <(b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)

Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20

Tony,

YTD spending is \$86.7M, an increase of \$8.3M from last week.

Spending driven by foundational research including the characterization of factors associated with severe disease, transmission dynamics, structural analysis of SARS-CoV-2 proteins. Small awards to support vaccine and therapeutic discovery.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, April 17, 2020 6:15 PM


To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel

(NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6)>;
Harper, Jill (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E]
<(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston,
Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E]
(b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon
(NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6)>;
Lee, Kun-Lin (NIH/NIAID) [E] <(b) (6)>; Bushar, Nicholas (NIH/NIAID) [E]
(b) (6)>; Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/17/20

Tony,

YTD spending is \$78.4M, an increase of \$10.9M from last week including costs to evaluate therapeutics in humans and NHPs, manufacture of a prototype virus-like vaccine candidate developed by Taubenberger/Memoli, and spending to accelerate discovery of new therapeutics, vaccines and diagnostics.



Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 10, 2020 8:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Erbelding, Emily (NIH/NIAID) [E] (b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/10/20

Tony,

YTD spending is \$67.5M, unchanged* from last week. A summary is attached.

I have also attached an updated budget plan reflecting our projected spending by research category by fiscal year. We are updating this weekly as we receive updates from the divisions on the timing of clinical trials, observational studies, natural history studies and research resource needs.

We will report mid-week on our YTD spending which will be in sync with the data the Dept. extracts.

Martin

-
-
-
- The reason that we have reported no weekly increase is to match our reported spending with the financial information that the Department is now extracting from our accounting system. We have always included spending from our regular appropriation, as directed by the Department. Now the guidance from the Dept. has been updated to report only spending from the supplemental COVID-19 appropriations.

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, April 3, 2020 8:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E]

(b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6) Harper, Jill (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/3/20

Tony,

YTD spending is \$67.5M , a weekly increase of \$45.9M mostly for initial funding for set-up of clinical trials for evaluation of remdesivir in patients with early disease stage and a placebo-controlled clinical trial of intravenous hyperimmune immunoglobulin (IVIG) in patients with COVID-19.

I've provided a summary spending plan the team worked on and a table for the \$1.532B that we have received in supplemental appropriations

- \$826M NIAID received 3/5/20 - the Coronavirus Preparedness and Response Supplemental Appropriations Act
- \$706M NIAID received 3/25/20 - the Coronavirus Aid, Relief, and Economic Security (CARES) Act

In the last document I've also included narrative summarizing activities funded by the \$249M Other NIH Institutes received in the CARES Act

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 27, 2020 7:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] <(b) (6)>; Crum, Wayne (NIH/NIAID) [E] <(b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6); Lane, Cliff (NIH/NIAID) [E] (b) (6); Rotrosen, Daniel (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston,

Hilary (NIH/NIAID) [E] <(b) (6)>; Lerner, Andrea (NIH/NIAID) [E]
(b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon
(NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)>;
Stover, Kathy (NIH/NIAID) [E] <(b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>;
Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E]
(b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/26/20

Tony,

YTD spending is \$21.6M , a weekly increase of \$4.0M for clinical trial site set-up for therapeutics, further vaccine development, small animal development, and therapeutic development (mAbs) and basic research.

Most of the \$50M-\$60M we listed last week we expect to be awarded before March 31. In many cases contractors have begun work without the award so as to not stall work.

Early next week I'll provide a summary spending plan for the additional \$706M that NIAID received in the supplemental appropriation signed by the President today.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, March 20, 2020 4:54 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E]
(b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.
(NIH/NIAID) [E] (b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>; Crum,
Wayne (NIH/NIAID) [E] (b) (6)>; Erbeling, Emily (NIH/NIAID) [E]
(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>

Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E]
(b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary
(NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] <(b) (6)>;
Doepel, Laurie (NIH/NIAID) [E] <(b) (6)>; Gilles, Sharon (NIH/NIAID) [E]
<(b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy
(NIH/NIAID) [E] (b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>; Lee, Kun-Lin
(NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6)
Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/19/20

Tony,

YTD spending is \$17.6M , a weekly increase of \$3.5M for clinical trial site set-up, therapeutic development (mAbs) and basic research.

We greatly appreciate all your hard work.

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 13, 2020 6:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] (b) (6)>; Law, Kim (NIH/NIAID) [E] (b) (6)>; Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)>; Bushar, Nicholas (NIH/NIAID) [E] (b) (6)>; Schneider, Johanna (NIH/NIAID) [E] (b) (6)>
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/12/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$1.5M for a total YTD spending of \$14.1M.

The \$1.5M increase is for the following:

\$1.0M awarded to set-up clinical sites at Emory and U. Washington Seattle for adaptable RCT of remdesivir.

\$0.4M supported data analysis of rhesus animal model and grant to gain understanding of the host pathways that regulate viral gene expression and viral subversion of the host immune system.

\$0.1M funded vaccine development at VRC and DIR



Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, March 6, 2020 5:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)
Subject: RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/5/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$0.2M for a total YTD spending of \$12.6M.

The \$0.2M increase is for vaccine candidate development at NIAID Intramural Labs including RML. Costs are mostly for staffing and overhead and include a preclinical immunogenicity

study designed to test the mRNA-1273 nCoV vaccine two-dose schedule in mice. The study will measure the immune response to this vaccine in an animal model in anticipation of clinical test in humans.

(b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, February 28, 2020 11:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6)
Cc: Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6)
Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 2/27/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$2.3M for a total YTD spending of \$12.4M.

A recap of the \$2.3 million spent in the last week is as follows:

- \$1.9M to set-up a Phase I trial (45 subjects) of the VRC/Moderna mRNA platform candidate at Kaiser Permanente Washington Health Research Institute (One of the VTEUs)

- \$0.3M that supported University of Hong Kong researchers in the development of a RT-PCR test to detect SARSCoV2 from human samples. The group has now shared the tests and relevant reagents with over 30 labs globally to enable diagnosis of COVID-19.
- \$0.1M vaccine candidate development at NIAID Intramural Labs

(b) (5)

Martin

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, February 14, 2020 3:56 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] (b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>; Crum, Wayne (NIH/NIAID) [E] (b) (6)>

Cc: Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6)>; Gilles, Sharon (NIH/NIAID) [E] (b) (6)

Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending as of 2/13/20

Dr. Fauci,

Attached is a narrative we are updating weekly for NIAID's COVID-19 response.

The accompanying spreadsheet summarizes the figures and includes a summary of our supplemental request.

We'll provide an update by Thursday of next week.

Martin

Resource Planning and Mission Integration Branch (RPMIB) – NIAID

NIH Bldg. 31 Room 7A47

Tel: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:22:37 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Cc: [REDACTED] (b) (6)
Subject: RE: RE:

Zeke:

Thanks for your note. [REDACTED] (b) (6) and I would love to get together with you all for dinner. Let us try to do so within a reasonably soon time frame.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] [REDACTED] (b) (6) > **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Saturday, May 2, 2020 7:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: FW: RE:

Email from Zeke Emanuel.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Emanuel, Ezekiel J [REDACTED] (b) (6) >
Sent: Friday, May 1, 2020 8:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: [REDACTED] (b) (6) >
Subject: Re: RE:

Tony

You are national--international --treasure. And we are depending upon your sanity and smarts.

We can have you and [REDACTED] (b) (6) over for dinner on the porch and order in from [REDACTED] (b) (6) or something. Anytime you are ready.

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [REDACTED] (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Friday, May 1, 2020 6:55 PM
To: Emanuel, Ezekiel J <[REDACTED] (b) (6)>
Cc: [REDACTED] (b) (6)
Subject: RE: RE:

Zeke:

Thanks for the note. Indeed, we do agree. [REDACTED] (b) (6)

[REDACTED] I look forward to chatting with you some time soon.

Best,
Tony

From: Emanuel, Ezekiel J <[REDACTED] (b) (6)>
Sent: Thursday, April 30, 2020 6:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Re: RE:

Sorry for misreading what you said--I think maybe I overintepreted--lots of finance people called and seemed like I was a downer compared to you. But I think we agree.

Are you and [REDACTED] (b) (6) doing okay?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [REDACTED] (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: Thursday, April 30, 2020 5:33 PM
To: Emanuel, Ezekiel J [REDACTED] (b) (6)>
Subject: RE:

Zeke:

I did not "strongly" endorse it. I specifically said that it was not a knockout drug and was only a baby step in the direction of developing more and better drugs. I said that it was important because it proved in a well-powered, randomized, placebo-controlled clinical trial that one can suppress the virus enough to see a clinical effect, as modest as the effect was. I do not think I forced anything.

Happy to chat with you about it.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6) >
Sent: Thursday, April 30, 2020 2:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject:

Tony,

I hope you and (b) (6) are doing well. You are doing an amazing job under difficult circumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!

I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bit forced?

My reading was the data were weak and in normal times for normal disease it is not enough to approve. And very unlikely to really impact COVID-19 disease pattern--regardless of supply issues.

Stay safe

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [REDACTED] (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 18:00:31 +0000
To: Hurst, Natalie R. EOP/OVP
Subject: RE: Update - White House Coronavirus Task Force Meeting

Thanks, Natalie!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

(b)(5) - PCP

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 17:57:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Greetings from India

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Prof. Chirantan Chatterjee <(b) (6)>
Sent: Saturday, May 2, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Deepak Bhatt Manager - Communications (b) (6)
Subject: Greetings from India

Dear Dr Fauci,

My greetings from India. I am a health economist and management professor at the Indian Institute of Management, Ahmedabad, India's premier management school. Also, i am a avid fan of your work even from pre-covid19 days.

I write to you requesting some time if possible to do a podcast of 45 minutes with you over zoom. The science and policy ecosystem in India i think would immensely benefit if you can offer your thoughts on what should be India's 12-month strategy going forward for COVID-19.

We have done some recent podcasts relatedly and they are listed her (<https://m.soundcloud.com/healthcastbycmhs/>).

If you agree, and we are flexible all of May, my communication head Mr. Deepak marked in the email will arrange the zoom logistics and make it as seamless as possible for you.

We will also go per your time zone conveniences and do this over webex/hangout/skype or phone call if that helps.

It would be a delight Dr. Fauci if you can join us in the conversation, looking forward to hearing from you. Our respectful namaste 🙏 from India for all the brave work you are doing.

My best, Chirantan

Chirantan Chatterjee (PhD, Carnegie Mellon) || Associate Professor (Economics & Business Policy) & ICICI Bank Chair in Strategic Management || Chairperson, Center for Management of Health Services at IIMA || 2019-2020 Visiting Fellow, 2018-2019 Campbell & Edward Teller National Fellow, Hoover Institution, Stanford University || Office Address: Wing 15F, Indian Institute of Management || Ahmedabad, 380 015 Gujarat, India || Skype: (b) (6) || Email: (b) (6) or (b) (6) || [Hoover Institution Website](#) | [IIMA Official Website](#)

What is laid down, ordered, factual is never enough to embrace the whole truth: life always spills over the rim of every cup. - Boris Pasternak in *Bridges to Infinity* : The Human Side of Mathematics (1983) by Michael Guillen

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 12:08:00 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Haskins, Melinda (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT
Attachments: Dr. Anthony Fauci - Town Hall Invite.pdf

Please take a look at this. We obviously will have to get clearance through HHS and White House Leg. This is for Thursday and so we would need to submit soon.

From: Coney, Lillie (b) (6)>
Sent: Friday, May 1, 2020 11:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Rushing, Glenn (b) (6); Coney, Lillie (b) (6)
Subject: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT

May 1, 2020

Dr. Anthony Fauci, M.D.
Director of the National Institute of Allergy and Infectious Diseases
Department of Health and Human Services
5601 Fishers Lane
Bethesda, MD 20892-9806

Dear Dr. Fauci:

Thank you for your tremendous steadfast leadership during this pandemic and health crisis. Our nation has not faced a crisis of this magnitude since the 1918 Spanish Flu, but we will travel this journey together and defeat this virus. In the end, the nation will become stronger and more prepared.

Your participation is requested in a Virtual Town Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDT. This town hall meeting will focus on testing and guidelines for re-opening our nation. It is scheduled to last an hour with 2 or 3 guests including yourself. Houston is the fourth largest city in the country and your knowledge and expertise would be most helpful in our fight to keep our infection and fatality rates low for this entire region and the State of Texas.

My office has been pushing testing and setting up testing sites since the first notification of the coronavirus. We currently have seven active testing sites and expanding each week to get to the mass testing necessary to flatten the infection rate.

Thank you for your consideration of this request and I look forward to participating with you in the Virtual Town Hall meeting. Again, thank you for your leadership. Please RSVP or if you have questions regarding this request with Glenn Rushing, my Chief of Staff at [REDACTED] (b) (6) and Lillie Coney, my Chief Policy Advisor at [REDACTED] (b) (6).

Very truly yours,

J

Sheila Jackson Lee
Member of Congress

Regards,
Lillie Coney
Policy Director
Congresswoman Sheila Jackson Lee (TX-18)
2079 Rayburn HOB
Washington, DC 20515

[REDACTED] (b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 12:01:04 +0000
To: [REDACTED] (b) (6)
Subject: FW: RE:

Let us try to do this next weekend.

From: Eisinger, Robert (NIH/NIAID) [E] [REDACTED] (On Behalf Of Fauci, Anthony (NIH/NIAID) [E])
Sent: Saturday, May 2, 2020 7:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: FW: RE:

Email from Zeke Emanuel.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Emanuel, Ezekiel J [REDACTED] (b) (6) >
Sent: Friday, May 1, 2020 8:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Cc: [REDACTED] (b) (6) >
Subject: Re: RE:

Tony

You are national--international --treasure. And we are depending upon your sanity and smarts.

We can have you and [REDACTED] (b) (6) over for dinner on the porch and order in from [REDACTED] (b) (6) or something. Anytime you are ready.

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) <>

Sent: Friday, May 1, 2020 6:55 PM

To: Emanuel, Ezekiel J (b) (6) <>

Cc: (b) (6) <>

Subject: RE: RE:

Zeke:

Thanks for the note. Indeed, we do agree. (b) (6)

(b) (6) I look forward to chatting with you some time soon.

Best,

Tony

From: Emanuel, Ezekiel J (b) (6) <>

Sent: Thursday, April 30, 2020 6:37 PM

To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) >

Subject: Re: RE:

Sorry for misreading what you said--I think maybe I overintepreted--lots of finance people called and seemed like I was a downer compared to you. But I think we agree.

Are you and (b) (6) doing okay?

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy [REDACTED] (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >

Sent: Thursday, April 30, 2020 5:33 PM

To: Emanuel, Ezekiel J [REDACTED] (b) (6) >

Subject: RE:

Zeke:

I did not "strongly" endorse it. I specifically said that it was not a knockout drug and was only a baby step in the direction of developing more and better drugs. I said that it was important because it proved in a well-powered, randomized, placebo-controlled clinical trial that one can suppress the virus enough to see a clinical effect, as modest as the effect was. I do not think I forced anything.

Happy to chat with you about it.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Emanuel, Ezekiel J (b) (6)

Sent: Thursday, April 30, 2020 2:12 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject:

Tony,

I hope you and (b) (6) are doing well. You are doing an amazing job under difficult circumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!

I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bit forced?

My reading was the data were weak and in normal times for normal disease it is not enough to to approve. And very unlikely to really impact COVID-19 disease pattern--regardless of supply issues.

Stay safe

Ezekiel J. Emanuel, M.D., Ph.D.

Vice Provost of Global Initiatives

Chair, Department of Medical Ethics and Health Policy (b) (6)

Levy University Professor

Co-Director, Healthcare Transformation Institute

Perelman School of Medicine and The Wharton School

University of Pennsylvania

Phone: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 2 May 2020 02:04:00 +0000
To: Selgrade, Sara (NIH/NIAID) [E]
Cc: NIAID OCGR Leg;Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Requesting your assistance: Draft NIAID Statement for May 12 Senate HELP Hearing
Attachments: 2020.05.12 NIAID Senate HELP testimony COVID 19 - with Fauci tracked changes.docx

I am attaching the document with minor tracked edits. Nice job! Thanks.

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, April 30, 2020 5:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Requesting your assistance: Draft NIAID Statement for May 12 Senate HELP Hearing

Dr. Fauci:

In preparation for the upcoming May 12th COVID-19 hearing of the Senate Health, Education, Labor, and Pensions Committee (Chair: Sen. Lamar Alexander, R-TN), we have drafted the attached NIAID testimony, building on your prior testimony on COVID-19. Drs. Giroir, Hahn, and Redfield also have been invited to the hearing.

We expect that your testimony will be included as an insert to an HHS-wide testimony. At the request of NIH OD, we have incorporated into the draft COVID-19 activities across NIH.

The testimony has been reviewed by the Divisions and Drs. Lane, Harper, Marston, and Lerner, as well as Courtney Billet, Greg Folkers, Martin Johnson, and Laurie Doepel.

NIH OLPA has asked to receive your testimony for clearance by tomorrow, if possible.

Thank you for your help.

Sara

Sara Selgrade, Ph.D.

Section Chief for Legislative Activities
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations

NIAID/NIH/DHHS

Bldg. 31, Room 7A17, MSC 2520

Bethesda, MD 20892-2520

Phone: (b) (6)

(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 15:28:23 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: clips

Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Sent: Friday, May 1, 2020 8:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Subject: RE: clips

Dr. Fauci –

I have requested the full clips from our clipping service. I found the following online in the meantime:

Today Show:

<https://www.today.com/video/dr-anthony-fauci-remdesivir-is-a-very-important-first-step-in-fighting-coronavirus-82800197863>

CNN Town Hall (clip discussing federal “reopening” guidelines):

<https://twitter.com/CNN/status/1256023483638669313>

CNN Town Hall (clip discussing vaccines):

<https://twitter.com/CNN/status/1256044817093558272>

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Friday, May 1, 2020 7:44 AM
To: Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Subject: clips

Jen:

Can we please make sure that I get the lips from yesterday from NBC Today Show and CNN Town Hall with Sanjay and Anderson.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:26:55 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: [REDACTED] (b) (4)

Another email from Andre Kalil.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Kalil, Andre C [REDACTED] (b) (6) >
Sent: Thursday, April 30, 2020 8:12 PM
To: Beigel, John (NIH) [E] [REDACTED] (b) (6); Dodd, Lori (NIH/NIAID) [E] [REDACTED] (b) (6);
Davey, Richard (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Lane, Cliff (NIH/NIAID) [E]
[REDACTED] (b) (6)>; Proschan, Michael (NIH/NIAID) [E] [REDACTED] (b) (6)>; Marston, Hilary
(NIH/NIAID) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: RE: [REDACTED] (b) (4)



Thanks,

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM

Professor

Department of Internal Medicine

Division of Infectious Diseases

Director, Transplant ID Program

Associate Editor, CMI, Official Journal of ESCMID

Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center

985400 Nebraska Medical Center, Omaha, NE 68198-5400

(b) (6) | fax 402.559-5581

(b) (6)

[UNMC](#) | [Facebook](#) | [Twitter](#) | [YouTube](#) | [Flickr](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."

Robert Ludlum - The Ambler Warning

From: Beigel, John (NIH) [E] (b) (6) >

Sent: Thursday, April 30, 2020 5:25 AM

To: Dodd, Lori (NIH/NIAID) [E] (b) (6) >; Kalil, Andre C (b) (6) >; Davey, Richard (NIH/NIAID) [E] <(b) (6) >; Lane, Cliff (NIH/NIAID) [E] <(b) (6) >; Proschan, Michael (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

Subject: Re: (b) (4)

Non-UNMC email

(b) (4)

--

John Beigel, M.D.

Associate Director for Clinical Research

Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

Phone: (b) (6)

email: (b) (6)

From: Lori Dodd (b) (6)>

Date: Thursday, April 30, 2020 at 6:05 AM

To: John Beigel (b) (6)>, Andre Kalil (b) (6)>, Richard Davey (b) (6)>, Cliff Lane <(b) (6)>, Michael Proschan (b) (6)>, Hilary Marston (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Subject: RE: (b) (4)

Andre-

I like what you wrote, and particularly like the first two sentences.

From: Beigel, John (NIH) [E] (b) (6)>

Sent: Thursday, April 30, 2020 5:53 AM

To: Kalil, Andre C (b) (6)>; Davey, Richard (NIH/NIAID) [E] <(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b) (6)>; Dodd, Lori (NIH/NIAID) [E] <(b) (6)>; Proschan, Michael (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: Re: (b) (4)

Andre,

(b) (4)

We too are open for further edits

John

--
John Beigel, M.D.

Associate Director for Clinical Research

Division of Microbiology and Infectious Diseases

National Institute of Allergy and Infectious Diseases (NIAID)

Phone: (b) (6)

email: (b) (6)

From: Andre Kalil (b) (6) >
Date: Thursday, April 30, 2020 at 3:19 AM
To: John Beigel (b) (6) >, Richard Davey (b) (6) >, Cliff Lane (b) (6), Lori Dodd (b) (6) >, Michael Proschan (b) (6) >, Hilary Marston < (b) (6) >, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
Subject: (b) (4)



Please let me know your thoughts and suggestions.

Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM

Professor

Department of Internal Medicine

Division of Infectious Diseases

Director, Transplant ID Program

Associate Editor, CMI, Official Journal of ESCMID

Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center

985400 Nebraska Medical Center, Omaha, NE 68198-5400

(b) (6) | fax 402.559-5581

(b) (6)

[UNMC](#) | [Facebook \[facebook.com\]](#) | [Twitter \[twitter.com\]](#) | [YouTube \[youtube.com\]](#) | [Flickr \[flickr.com\]](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."

Robert Ludlum - The Ambler Warning

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:25:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email: (b) (6)

From: Dani Bolognesi, Ph.D. (b) (6)
Sent: Thursday, April 30, 2020 8:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: RE:

TX Tony. Nice touch reminding folks of how AZT propelled the pharmas and great to see things moving with this beast!

Sei un campione!

Dani

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, April 30, 2020 7:58 PM
To: Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] (b) (6)
Subject: FW:

Cristina:

Please take a good look at this. It is from Dani Bolognesi, one of our top HIV/AIDS investigators from a few years back. He is a serious scientist. Let me know what you think.
Thanks,
Tony

From: Eisinger, Robert (NIH/NIAID) [E] (b) (6)> **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Monday, April 27, 2020 6:57 PM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: FW:

Email from Dani Bolognesi.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)

From: Dani Bolognesi, Ph.D. [REDACTED] (b) (6) >
Sent: Monday, April 27, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C]
[REDACTED] (b) (6) >
Subject: FW:

Kimberly: Please see that this reaches Tony as per our call today.

TX in advance.

Dani

Hi Tony:

In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:



We are prepared to discuss this with you and your team at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEx as an initial step.

Many thanks for the opportunity to share this with you!

All the very best,

Dani

(b) (6)

Best,

Dani

Sent from Dani Bolognesi

From: "Dani Bolognesi, Ph.D." <(b) (6)>

Date: Monday, April 27, 2020 at 2:53 PM

To: "Matthias Gromeier, M.D." (b) (6)

Subject: Please review this draft email to Tony--TX

Matthias: Please review and edit the proposed email to Tony.

Dani

Hi Tony: In advance of getting together with you and your team, I am forwarding a short presentation for you guys to look at. The key elements are follows:

We are prepared to discuss this with you and your tea at any time that is convenient for you. As you may know, we are locked down here in the Research Triangle until May 15. If it makes sense, we could arrange a WebEX as an initial step.

All the best,

Dani

Best,

Dani

Sent from Dani Bolognesi

The information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person, including anyone who believes he/she might have received it due to an addressing error, is requested to notify the sender immediately by return electronic mail, and to delete it without further reading or retention. The information is not to be forwarded to or shared unless in compliance with Duke Health policies on confidentiality and/or with the approval of the sender.

From: Eisinger, Robert (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 12:10:09 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FW: ACTT publication
Importance: High

Another email from Andre Kalil.

Robert W. Eisinger, Ph.D.
Special Assistant for Scientific Projects
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
31 Center Drive, Room 7A-03
Bethesda MD 20892
Telephone: (b) (6)
Email (b) (6)

From: Kalil, Andre C (b) (6) >
Sent: Friday, May 1, 2020 2:59 AM
To: Beigel, John (NIH) [E] (b) (6) >; Davey, Richard (NIH/NIAID) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6); Dodd, Lori (NIH/NIAID) [E] (b) (6) >; Proschan, Michael (NIH/NIAID) [E] (b) (6) Marston, Hilary (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: ACTT publication
Importance: High

Not my first choice, but I want to share the invitation email below with you.
Andre

Andre Kalil, MD, MPH, FACP, FIDSA, FCCM
Professor
Department of Internal Medicine
Division of Infectious Diseases
Director, Transplant ID Program
Associate Editor, CMI, Official Journal of ESCMID
Editorial Board, CCM, Official Journal of SCCM



University of Nebraska Medical Center
985400 Nebraska Medical Center, Omaha, NE 68198-5400
(b) (6) | fax 402.559-5581
(b) (6)

[UNMC](#) | [Facebook](#) | [Twitter](#) | [YouTube](#) | [Flickr](#)

"Lucky? Obviously you haven't heard anything I've said. It was a matter of applying Bayes' Theorem to estimate the conditional probabilities. Giving due weight to the prior probabilities..."
Robert Ludlum - The Ambler Warning

From: [REDACTED] (b) (4)

Sent: Thursday, April 30, 2020 1:03 PM

To: Kalil, Andre C [REDACTED] (b) (6)

Subject: ACTT publication

Importance: High

Non-UNMC email

Dear Dr. Kalil,

(b) (4)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 11:38:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: interview request by Greek newspaper Ethnos

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Γιώργος Σκαφιδάς <gskafidas@ethnos.gr>
Sent: Friday, May 1, 2020 6:07 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: interview request by Greek newspaper Ethnos

Dear Dr. Fauci,

my name is George Skafidas and I'm a journalist working for the Greek national weekly ETHNOS (www.ethnos.gr).

We would be very much interested in doing an interview with you, to be published in the Sunday edition of the paper, regarding the developments surrounding the COVID-19 pandemic.

Best regards

ΕΘΝΟΣ

George Skafidas

Senior editor, World Affairs

tel: +30 210 6510550

mob: [REDACTED] (b) (6)

Οι πληροφορίες που περιέχονται σε αυτό το μήνυμα ηλεκτρονικού ταχυδρομείου (e-mail) καθώς και σε τυχόν συνημμένα είναι εμπιστευτικές και προορίζονται για χρήση αποκλειστικά από το συγκεκριμένο παραλήπτη (-ες). Οι πληροφορίες αυτές μπορεί να καλύπτονται από επιχειρησιακό ή άλλο απόρρητο ή άλλους νόμους και δεν επιτρέπεται να ανακοινωθούν σε οποιονδήποτε τρίτο. Σε περίπτωση που δεν είστε ο παραλήπτης του μηνύματος ή το πρόσωπο που είναι αρμόδιο για την παράδοσή του στον παραλήπτη, απαγορεύεται να το ανακοινώσετε, αντιγράψετε, διανείμετε ή διατηρήσετε εν όλων ή εν μέρει.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 1 May 2020 11:38:08 +0000
To: [REDACTED] (b) (6)
Subject: RE: Coronavirus: Covid 19

Ato:

Thank you for your note. We will know soon whether hydroxychloroquine has any beneficial effects as the results of randomized, controlled trials become available. The pathogenesis of COVID-19 is still an open question. You are correct in that there is a more recent tendency to use ventilators only as a very last resort since oxygenation rather than ventilation appears to be key to recovery.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: gabriel stephens [REDACTED] (b) (6)
Sent: Friday, May 1, 2020 4:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Coronavirus: Covid 19

Hi Dr Fauci,

Please find an audio attached of a doctor describing the experience with regards to covid 19 in the hospital. She seems to suggest covid 19 is a virus that rather attacks the blood cell, leading to respiratory and other organ complications, hence they need to look at treatment in a different light. In the UK some hospitals have moved away from using ventilators due to the high death rate of those on ventilators, and are rather using ventilators for sleep apnea, as they are less invasive, and the results are much much better compared to invasive ventilators

There are some anecdotal observations I have also made. The infection rate in most African countries seem to be comparatively low, which could possibly be due to the rate of testing being conducted. However the death rates are also comparatively very low. From initial information with regards to

hydroxychloroquine and some antimalaria drugs usage, it was suggested that those who were alleged to have had some benefits had mild symptoms of covid 19. I know some clinical trials have shown hydroxychloroquine not to be effective in the treatment of covid 19 in very ill patients. However, my hypothesis is, are the low death rates in Africa linked to the fact that malaria is very prevalent in Africa, and lots of Africans take antimalarial drugs, making them less susceptible to covid 19, hence the low death rate. Is there a similar trend in other countries where malaria is prevalent? Is there an unintended benefit of taking antimalarial drug (or other medication) before covid infection, or at the onset, making people less susceptible to covid19.

As I said, this is based on anecdotal observations.

Yours sincerely

Ato Stephens